{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Chronic+Lymphocytic+Leukemia&q=venetoclax",
    "query": {
      "condition": "Chronic Lymphocytic Leukemia",
      "intervention": "venetoclax"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 103,
    "total_pages": 11,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Chronic+Lymphocytic+Leukemia&q=venetoclax&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-24T22:25:13.829Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03045328",
      "title": "Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Chronic Lymphocytic Leukemia",
        "Recurrent Small Lymphocytic Lymphoma",
        "Refractory Chronic Lymphocytic Leukemia",
        "Refractory Small Lymphocytic Lymphoma"
      ],
      "interventions": [
        {
          "name": "Ibrutinib",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Steven E. Coutre",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 22,
      "start_date": "2017-09-26",
      "completion_date": "2021-08-05",
      "has_results": true,
      "last_update_posted_date": "2021-09-29",
      "last_synced_at": "2026-07-24T22:25:13.829Z",
      "location_count": 2,
      "location_summary": "Duarte, California • Stanford, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03045328"
    },
    {
      "nct_id": "NCT02427451",
      "title": "Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Chronic Lymphocytic Leukemia",
        "Refractory Chronic Lymphocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "Bcl-2 Inhibitor GDC-0199",
          "type": "DRUG"
        },
        {
          "name": "Obinutuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ibrutinib",
          "type": "DRUG"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Kerry Rogers",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 87,
      "start_date": "2015-08-03",
      "completion_date": "2027-04-15",
      "has_results": true,
      "last_update_posted_date": "2026-06-15",
      "last_synced_at": "2026-07-24T22:25:13.829Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02427451"
    },
    {
      "nct_id": "NCT04553692",
      "title": "Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor",
        "Colorectal Cancer",
        "Non Hodgkin Lymphoma",
        "Sarcoma",
        "Chondrosarcoma",
        "Small Lymphocytic Lymphoma",
        "Chronic Lymphocytic Leukemia",
        "Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Aplitabart (IGM-8444)",
          "type": "DRUG"
        },
        {
          "name": "FOLFIRI",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab (and approved biosimilars)",
          "type": "DRUG"
        },
        {
          "name": "Birinapant",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "IGM Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 272,
      "start_date": "2020-09-23",
      "completion_date": "2025-01-20",
      "has_results": false,
      "last_update_posted_date": "2025-03-28",
      "last_synced_at": "2026-07-24T22:25:13.829Z",
      "location_count": 37,
      "location_summary": "Phoenix, Arizona • Duarte, California • Los Alamitos, California + 29 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Los Alamitos",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04553692"
    },
    {
      "nct_id": "NCT04965493",
      "title": "A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Lymphocytic Leukemia",
        "Small Lymphocytic Lymphoma"
      ],
      "interventions": [
        {
          "name": "Pirtobrutinib",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Loxo Oncology, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 600,
      "start_date": "2021-09-20",
      "completion_date": "2027-10",
      "has_results": false,
      "last_update_posted_date": "2026-01-29",
      "last_synced_at": "2026-07-24T22:25:13.829Z",
      "location_count": 41,
      "location_summary": "Chandler, Arizona • Phoenix, Arizona • Orange, California + 32 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Santa Rosa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04965493"
    },
    {
      "nct_id": "NCT04560322",
      "title": "Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Lymphocytic Leukemia",
        "Small Lymphocytic Lymphoma"
      ],
      "interventions": [
        {
          "name": "Venetoclax",
          "type": "DRUG"
        },
        {
          "name": "Obinutuzumab",
          "type": "DRUG"
        },
        {
          "name": "Acalabrutinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2020-10-19",
      "completion_date": "2029-03-01",
      "has_results": false,
      "last_update_posted_date": "2026-04-13",
      "last_synced_at": "2026-07-24T22:25:13.829Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04560322"
    },
    {
      "nct_id": "NCT02756611",
      "title": "A Study to Evaluate the Efficacy of Venetoclax Monotherapy in Relapsed/Refractory Participants With Chronic Lymphocytic Leukemia (CLL)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Chronic Lymphocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "Venetoclax",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 258,
      "start_date": "2016-06-22",
      "completion_date": "2022-03-11",
      "has_results": true,
      "last_update_posted_date": "2023-04-10",
      "last_synced_at": "2026-07-24T22:25:13.829Z",
      "location_count": 6,
      "location_summary": "Louisville, Kentucky • Baltimore, Maryland • Hackensack, New Jersey + 3 more",
      "locations": [
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Hackensack",
          "state": "New Jersey"
        },
        {
          "city": "Salt Lake City",
          "state": "Utah"
        },
        {
          "city": "Spokane",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02756611"
    },
    {
      "nct_id": "NCT03801525",
      "title": "Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Chronic Lymphocytic Leukemia",
        "Small Lymphocytic Lymphoma"
      ],
      "interventions": [
        {
          "name": "Ublituximab",
          "type": "DRUG"
        },
        {
          "name": "Umbralisib",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "TG Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 277,
      "start_date": "2019-05-16",
      "completion_date": "2022-12-20",
      "has_results": true,
      "last_update_posted_date": "2024-04-19",
      "last_synced_at": "2026-07-24T22:25:13.829Z",
      "location_count": 50,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 45 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03801525"
    },
    {
      "nct_id": "NCT03547115",
      "title": "A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Follicular Lymphoma (FL)",
        "Mantle Cell Lymphoma (MCL)",
        "Marginal Zone Lymphoma (MZL)",
        "Small Lymphocytic Lymphoma (SLL)",
        "Chronic Lymphocytic Leukemia (CLL)",
        "Diffuse Large B-cell Lymphoma (DLBCL)",
        "Acute Myeloid Leukemia (AML)"
      ],
      "interventions": [
        {
          "name": "voruciclib monotherapy",
          "type": "DRUG"
        },
        {
          "name": "voruciclib and venetoclax",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "MEI Pharma, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 84,
      "start_date": "2018-05-31",
      "completion_date": "2024-07-24",
      "has_results": false,
      "last_update_posted_date": "2026-03-17",
      "last_synced_at": "2026-07-24T22:25:13.829Z",
      "location_count": 12,
      "location_summary": "Duarte, California • Chicago, Illinois • Boston, Massachusetts + 9 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03547115"
    },
    {
      "nct_id": "NCT02639910",
      "title": "Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia, Lymphocytic, Chronic, B-Cell",
        "Chronic Lymphocytic Leukemia",
        "Small Lymphocytic Lymphoma"
      ],
      "interventions": [
        {
          "name": "Tafasitamab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Idelalisib",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "MorphoSys AG",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2016-11",
      "completion_date": "2021-12",
      "has_results": true,
      "last_update_posted_date": "2021-12-20",
      "last_synced_at": "2026-07-24T22:25:13.829Z",
      "location_count": 3,
      "location_summary": "Jacksonville, Florida • Rochester, Minnesota • Columbus, Ohio",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02639910"
    },
    {
      "nct_id": "NCT07690891",
      "title": "Nemtabrutinib With Venetoclax and Obinutuzumab in Patients With Chronic Lymphocytic Leukemia",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Lymphocytic Leukemia"
      ],
      "interventions": [
        {
          "name": "Nemtabrutinib",
          "type": "DRUG"
        },
        {
          "name": "Venetoclax",
          "type": "DRUG"
        },
        {
          "name": "Obinutuzumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Medical College of Wisconsin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2026-10-01",
      "completion_date": "2031-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-08",
      "last_synced_at": "2026-07-24T22:25:13.829Z",
      "location_count": 1,
      "location_summary": "Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07690891"
    }
  ]
}